专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明授权

US07868472B2 Thermal dissipation in integrated circuit systems 有权
标题翻译：集成电路系统中的散热
公开(公告)号：US07868472B2
公开(公告)日：2011-01-11
申请号：US10820484
申请日：2004-04-08
申请人： Michael G. Kelly
发明人： Michael G. Kelly
IPC分类号： H01L23/28
CPC分类号： H01L23/367 , H01L23/3675 , H01L24/48 , H01L24/81 , H01L2224/48091 , H01L2224/81801 , H01L2224/82 , H01L2224/85 , H01L2224/86 , H01L2924/00014 , H01L2924/01079 , H01L2924/09701 , H01L2924/14 , H01L2924/15311 , H01L2924/00 , H01L2224/45099 , H01L2224/45015 , H01L2924/207
摘要： Integrated circuit systems with thermal dissipation enhancement features are described. In one aspect, an integrated circuit system includes a die incorporating an integrated circuit. The die has a top side and a bottom side. The top side supports an electrical signal communication metallization and a top side thermal dissipation metallization. The bottom side supports a bottom side thermal dissipation metallization.
摘要翻译：描述了具有散热增强特征的集成电路系统。在一个方面，集成电路系统包括结合有集成电路的管芯。模具具有顶侧和底侧。顶侧支持电信号通信金属化和顶侧散热金属化。底侧支撑底侧散热金属化。

62. 发明申请

US20080312237A1 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same 审中-公开
公开(公告)号：US20080312237A1
公开(公告)日：2008-12-18
申请号：US12218973
申请日：2008-07-18
申请人： Michael G. Kelly , Satyanarayana Janagani , Ravindra B. Upasani
发明人： Michael G. Kelly , Satyanarayana Janagani , Ravindra B. Upasani
IPC分类号： A61K31/5375 , C07D265/30 , C07D239/42 , C07D471/04 , C07D221/12 , C07D215/38 , C07D213/00 , C07D211/70 , C07D277/46 , C07D233/88 , A61K31/357 , A61K31/381 , A61K31/40 , A61K31/426 , A61K31/44 , A61K31/435 , A61K31/47 , A61K31/473 , A61K31/4375 , A61P17/06 , A61P19/02 , A61P25/08 , A61P25/06 , A61P25/24 , A61P25/28 , A61K31/36 , C07D233/56 , C07D207/08 , C07D333/06 , C07D319/16 , C07D317/46 , C07C233/76 , A61K31/505
CPC分类号： C07D319/18 , C04B35/632 , C07C233/65 , C07C233/66 , C07C233/69 , C07C233/73 , C07C233/75 , C07C255/60 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/10 , C07D207/337 , C07D209/08 , C07D209/14 , C07D209/16 , C07D209/18 , C07D209/88 , C07D211/34 , C07D211/58 , C07D213/40 , C07D213/53 , C07D213/56 , C07D213/70 , C07D213/75 , C07D213/82 , C07D215/12 , C07D215/38 , C07D217/02 , C07D221/10 , C07D221/12 , C07D221/14 , C07D231/40 , C07D233/54 , C07D233/61 , C07D233/64 , C07D239/42 , C07D277/46 , C07D295/13 , C07D295/135 , C07D307/14 , C07D307/52 , C07D307/54 , C07D317/50 , C07D317/58 , C07D319/12 , C07D333/20 , C07D333/24 , C07D401/06 , C07D401/12 , C07D405/06 , C07D405/12 , C07D409/06
摘要： Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

63. 发明授权

US07432281B2 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same 失效
标题翻译：酰胺衍生物作为离子通道配体和药物组合物及其使用方法
公开(公告)号：US07432281B2
公开(公告)日：2008-10-07
申请号：US10961483
申请日：2004-10-07
申请人： Michael G. Kelly , Satyanarayana Janagani , Ravindra B. Upasani
发明人： Michael G. Kelly , Satyanarayana Janagani , Ravindra B. Upasani
IPC分类号： A61K31/44 , A61K31/47 , C07D213/02 , C07D217/02
CPC分类号： C07D319/18 , C04B35/632 , C07C233/65 , C07C233/66 , C07C233/69 , C07C233/73 , C07C233/75 , C07C255/60 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/10 , C07D207/337 , C07D209/08 , C07D209/14 , C07D209/16 , C07D209/18 , C07D209/88 , C07D211/34 , C07D211/58 , C07D213/40 , C07D213/53 , C07D213/56 , C07D213/70 , C07D213/75 , C07D213/82 , C07D215/12 , C07D215/38 , C07D217/02 , C07D221/10 , C07D221/12 , C07D221/14 , C07D231/40 , C07D233/54 , C07D233/61 , C07D233/64 , C07D239/42 , C07D277/46 , C07D295/13 , C07D295/135 , C07D307/14 , C07D307/52 , C07D307/54 , C07D317/50 , C07D317/58 , C07D319/12 , C07D333/20 , C07D333/24 , C07D401/06 , C07D401/12 , C07D405/06 , C07D405/12 , C07D409/06
摘要： Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.
摘要翻译：公开了具有下列化学式的化合物：化合物可以制备成药物组合物，并且可以用于预防和治疗哺乳动物包括人的多种病症，包括作为非限制性实例的疼痛，炎症，创伤性损伤等。

64. 发明授权

US07338950B2 Amide compounds as ion channel ligands and uses thereof 失效
标题翻译：酰胺化合物作为离子通道配体及其用途
公开(公告)号：US07338950B2
公开(公告)日：2008-03-04
申请号：US10962195
申请日：2004-10-07
申请人： Michael G. Kelly , Satyanarayana Janagani , Guoxian Wu , John Kincaid
发明人： Michael G. Kelly , Satyanarayana Janagani , Guoxian Wu , John Kincaid
IPC分类号： C07D401/10 , A61K31/444
CPC分类号： C07D405/12 , C04B35/632 , C07D213/56 , C07D213/61 , C07D213/64 , C07D213/70 , C07D213/75 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14
摘要： Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.
摘要翻译：公开了具有下列化学式的化合物：化合物可以制备成药物组合物，并且可以用于预防和治疗哺乳动物包括人的多种病症，包括作为非限制性实例的疼痛，炎症，创伤性损伤等。

65. 发明授权

US07297700B2 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof 失效
公开(公告)号：US07297700B2
公开(公告)日：2007-11-20
申请号：US11384045
申请日：2006-03-17
申请人： Michael G. Kelly , John Kincaid
发明人： Michael G. Kelly , John Kincaid
IPC分类号： A01N43/54 , A01N43/90 , A61K31/517 , A61K31/519 , C07D239/00 , C07D239/70
CPC分类号： C07D217/24 , C07D401/06 , C07D405/06 , C07D413/06 , C07D417/06 , C07D471/04 , C07D487/04
摘要： Bicycloheteroaryl compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

66. 发明授权

US07202546B2 Integrated circuit with copper interconnect and top level bonding/interconnect layer 有权
标题翻译：集成电路与铜互连和顶层接合/互连层
公开(公告)号：US07202546B2
公开(公告)日：2007-04-10
申请号：US10678980
申请日：2003-10-03
申请人： Salvador Salcido, Jr. , Michael G. Kelly , Michael D. Cusack , Ravindhar K. Kaw
发明人： Salvador Salcido, Jr. , Michael G. Kelly , Michael D. Cusack , Ravindhar K. Kaw
IPC分类号： H01L29/00 , H01L23/58
CPC分类号： H01L24/05 , H01L23/5286 , H01L23/53228 , H01L24/06 , H01L24/48 , H01L2224/04042 , H01L2224/05556 , H01L2224/05599 , H01L2224/48091 , H01L2224/48227 , H01L2224/85399 , H01L2924/00014 , H01L2924/01013 , H01L2924/01029 , H01L2924/01033 , H01L2924/014 , H01L2924/14 , H01L2924/181 , H01L2224/45099 , H01L2924/00
摘要： An integrated circuit including a copper interconnection layer includes an aluminum distribution layer overlying the copper interconnection layer to distribute external electrical signals such as power, ground, and clock signals throughout the die of the device. The distribution layer overlies the copper interconnection layer in a grid pattern which connects to the copper interconnection layer through a plurality of vias. The distribution layer further includes a plurality of wire bond pads to permit wire bonding between the distribution layer and bonding pads of the integrated circuit package.
摘要翻译：包括铜互连层的集成电路包括覆盖铜互连层的铝分布层，以在设备的整个管芯中分布诸如电源，接地和时钟信号的外部电信号。分布层通过多个通孔连接到铜互连层的栅格图案覆盖铜互连层。分布层还包括多个引线接合焊盘，以允许分布层和集成电路封装的焊盘之间的引线接合。

67. 发明授权

US07176322B2 Calcium receptor modulating agents 有权
标题翻译：钙受体调节剂
公开(公告)号：US07176322B2
公开(公告)日：2007-02-13
申请号：US10444945
申请日：2003-05-22
申请人： Michael G. Kelly , Shimin Xu , Ning Xi , Robert Townsend , David Semin , Chiara Ghiron , Thomas Coulter
发明人： Michael G. Kelly , Shimin Xu , Ning Xi , Robert Townsend , David Semin , Chiara Ghiron , Thomas Coulter
IPC分类号： C07D209/82 , C07D209/14 , C07D209/04 , A61K31/403 , A61K31/404 , A61K31/4045
CPC分类号： C07D235/06 , C07D209/08 , C07D209/10 , C07D209/12 , C07D209/86 , C07D209/88 , C07D249/04 , C07D401/04 , C07D403/04 , C07D413/04 , C07D471/04 , C07D491/04
摘要： The compounds of the invention are represented by the following general structure or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
摘要翻译：本发明的化合物由以下一般结构或其药学上可接受的盐以及含有它们的组合物表示，其中变量在本文中定义，及其用于减少或抑制PTH分泌的用途，包括减少或抑制PTH分泌的方法，以及用于治疗或预防与骨疾病相关的疾病如骨质疏松症或与过度分泌的PTH相关的疾病如甲状旁腺功能亢进的方法。本发明还涉及制备这些化合物的方法以及在这些方法中有用的中间体。

68. 发明授权

US07115607B2 Substituted piperazinyl amides and methods of use 有权
标题翻译：取代的哌嗪基酰胺和使用方法
公开(公告)号：US07115607B2
公开(公告)日：2006-10-03
申请号：US10202823
申请日：2002-07-24
申请人： Christopher H. Fotsch , Premilla Arasasingham , Yunxin Bo , Ning Chen , Martin H. Goldberg , Nianhe Han , Feng-Yin Hsieh , Michael G. Kelly , Qingyian Liu , Mark H. Norman , Duncan M. Smith , Markian Stec , Nuria Tamayo , Ning Xi , Shimin Xu
发明人： Christopher H. Fotsch , Premilla Arasasingham , Yunxin Bo , Ning Chen , Martin H. Goldberg , Nianhe Han , Feng-Yin Hsieh , Michael G. Kelly , Qingyian Liu , Mark H. Norman , Duncan M. Smith , Markian Stec , Nuria Tamayo , Ning Xi , Shimin Xu
IPC分类号： A61K31/496 , C07D401/12 , C07D403/12
CPC分类号： C07D207/08 , A61K38/00 , C07D205/04 , C07D207/09 , C07D209/14 , C07D209/42 , C07D211/26 , C07D211/60 , C07D211/62 , C07D213/38 , C07D213/81 , C07D213/82 , C07D215/48 , C07D217/06 , C07D217/14 , C07D217/26 , C07D233/64 , C07D295/185 , C07D317/60 , C07D317/68 , C07D319/18 , C07D401/12 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D451/02 , C07K5/06026 , C07K5/06139 , C07K5/06147 , C07K5/06191
摘要： Selected substituted piperazine compounds of Formula I are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
摘要翻译：式I的选择性取代哌嗪化合物对预防和治疗诸如肥胖症等疾病是有效的。本发明包括新颖的化合物，类似物，前药和药学上可接受的盐，用于预防和治疗涉及黑皮质素受体活化的疾病和其它疾病或病症的药物组合物和方法。本发明还涉及制备这些化合物的方法以及在这些方法中有用的中间体。

69. 发明授权

US07049330B2 Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents 失效
标题翻译：环烷基取代的芳基哌嗪，哌啶和四氢吡啶作为血清素能药
公开(公告)号：US07049330B2
公开(公告)日：2006-05-23
申请号：US10340087
申请日：2003-01-10
申请人： Wayne E. Childers , Michael G. Kelly , Yvette L. Palmer , Edward J. Podlesny
发明人： Wayne E. Childers , Michael G. Kelly , Yvette L. Palmer , Edward J. Podlesny
IPC分类号： A61K31/445 , C07D211/26
CPC分类号： C07D239/42 , C07D209/08 , C07D211/22 , C07D213/74 , C07D217/22 , C07D277/82 , C07D295/125 , C07D295/13 , C07D319/20
摘要： This invention relates to compounds which have activity as 5-HT1A agonists and antagonists which may be useful for the treatment of anxiety, depression, cognitive deficits, and prostate cancer, having the formula wherein: X is a moiety selected from the group of: n is selected from the integers 1 through 5; R1 is optionally substituted aryl or mono or bicyclic heteroaryl, with a proviso that heteroaryl is not thiadiazole; R2 is H or alkyl; R3 is H, COR5, COOR5, and CONR5R6; R4 is H, alkyl, alkenyl, alkynyl, aryl, mono or bicyclic heteroaryl, aralkyl, and mono or bicyclic heteroaralkyl, wherein the aryl or heteroaryl groups are optionally substituted; R5 and R6 are H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, adamantyl, and noradamantyl or R5 and R6 taken together may form a 5–7 membered azacyclic ring, optionally containing an additional heteroatom selected from O, S, or NR4; when R5 or R6 are chosen from cycloalkyl or cycloalkenyl, the cyclic group may optionally be substituted at the 1-position with a C1–C3 alkyl group; or an optical isomer; or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明涉及具有下式的化合物，其具有作为5-HT 1A激动剂和拮抗剂的活性，其可用于治疗焦虑，抑郁，认知缺陷和前列腺癌，其中：X为选自以下的基团：n选自整数1至5; R 1是任选取代的芳基或单或双环杂芳基，条件是杂芳基不是噻二唑; R 2是H或烷基; R 3是H，COR 5，COOR 5和CONR 5 R 6 O / >; R 4是H，烷基，烯基，炔基，芳基，单或双环杂芳基，芳烷基和单或双环杂芳烷基，其中芳基或杂芳基任选被取代; R 5和R 6是H，烷基，烯基，炔基，环烷基，环烯基，金刚烷基和去月桂外基或R 5和R 共同组合可以形成5-7元的氮杂环，任选地含有选自O，S或NR 4的另外的杂原子。当R 5或R 6选自环烷基或环烯基时，环状基团可以任选地在1位被C 1〜 -C 3烷基; 或光学异构体; 或其药学上可接受的盐。

70. 发明授权

US07026320B2 Serotonergic agents 失效
公开(公告)号：US07026320B2
公开(公告)日：2006-04-11
申请号：US10441536
申请日：2003-05-20
申请人： Wayne E. Childers , Michael G. Kelly , Sharon J. Rosenzweig-Lipson
发明人： Wayne E. Childers , Michael G. Kelly , Sharon J. Rosenzweig-Lipson
IPC分类号： A61K31/496
CPC分类号： C07D405/12
摘要： Novel piperazine derivatives are provided having the formula wherein R1 is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof, which are useful as 5-HT1A receptor antagonists.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式